<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:31:59Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10414727" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10414727</identifier>
        <datestamp>2023-08-11</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10414727</article-id>
              <article-id pub-id-type="pmcid">PMC10414727</article-id>
              <article-id pub-id-type="pmc-uid">10414727</article-id>
              <article-id pub-id-type="pmid">37058687</article-id>
              <article-id pub-id-type="pmid">37058687</article-id>
              <article-id pub-id-type="publisher-id">JCO.22.02152</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.22.02152</article-id>
              <article-id pub-id-type="art-access-id">00008</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>CLINICAL TRIAL UPDATES</subject>
                  <subj-group>
                    <subject>Gynecologic Cancer</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9793-7614</contrib-id>
                  <name>
                    <surname>Makker</surname>
                    <given-names>Vicky</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2225-715X</contrib-id>
                  <name>
                    <surname>Colombo</surname>
                    <given-names>Nicoletta</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="con14" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Herr√°ez</surname>
                    <given-names>Antonio Casado</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6985-0159</contrib-id>
                  <name>
                    <surname>Monk</surname>
                    <given-names>Bradley J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mackay</surname>
                    <given-names>Helen</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="con6" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Santin</surname>
                    <given-names>Alessandro D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8215-5887</contrib-id>
                  <name>
                    <surname>Miller</surname>
                    <given-names>David S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5598-5263</contrib-id>
                  <name>
                    <surname>Moore</surname>
                    <given-names>Richard G.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9748-1458</contrib-id>
                  <name>
                    <surname>Baron-Hay</surname>
                    <given-names>Sally</given-names>
                  </name>
                  <degrees>MBBS</degrees>
                  <xref rid="aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="con15" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2472-8306</contrib-id>
                  <name>
                    <surname>Ray-Coquard</surname>
                    <given-names>Isabelle</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="con10" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6087-8873</contrib-id>
                  <name>
                    <surname>Ushijima</surname>
                    <given-names>Kimio</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7624-7611</contrib-id>
                  <name>
                    <surname>Yonemori</surname>
                    <given-names>Kan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                  <xref rid="con7" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>Yong Man</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Guerra Alia</surname>
                    <given-names>Eva M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0062-6105</contrib-id>
                  <name>
                    <surname>Sanli</surname>
                    <given-names>Ulus A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bird</surname>
                    <given-names>Steven</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="aff16" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                  <xref rid="con16" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Orlowski</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff16" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                  <xref rid="con11" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6345-1218</contrib-id>
                  <name>
                    <surname>McKenzie</surname>
                    <given-names>Jodi</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                  <xref rid="con1" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5621-9138</contrib-id>
                  <name>
                    <surname>Okpara</surname>
                    <given-names>Chinyere</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                  <xref rid="con13" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barresi</surname>
                    <given-names>Gianmaria</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff19" ref-type="aff">
                    <sup>19</sup>
                  </xref>
                  <xref rid="con8" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0981-0598</contrib-id>
                  <name>
                    <surname>Lorusso</surname>
                    <given-names>Domenica</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff20" ref-type="aff">
                    <sup>20</sup>
                  </xref>
                  <xref rid="con19" ref-type="fn"/>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York City, NY</aff>
                <aff id="aff2"><label><sup>2</sup></label>Gynecologic Oncology Department, University of Milan-Bicocca, European Institute of Oncology IRCCS, Milan, Italy</aff>
                <aff id="aff3"><label><sup>3</sup></label>Medical Oncology Department, Hospital Clinico Universitario San Carlos, Madrid, Spain</aff>
                <aff id="aff4"><label><sup>4</sup></label>HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ</aff>
                <aff id="aff5"><label><sup>5</sup></label>Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada</aff>
                <aff id="aff6"><label><sup>6</sup></label>Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT</aff>
                <aff id="aff7"><label><sup>7</sup></label>Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX</aff>
                <aff id="aff8"><label><sup>8</sup></label>Division of Gynecologic Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY</aff>
                <aff id="aff9"><label><sup>9</sup></label>Medical Oncology Department, Royal North Shore Hospital, St Leonards, NSW, Australia</aff>
                <aff id="aff10"><label><sup>10</sup></label>Medical Oncology Department, Centre L√©on B√©rard, University Claude Bernard, GINECO Group, Lyon, France</aff>
                <aff id="aff11"><label><sup>11</sup></label>Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan</aff>
                <aff id="aff12"><label><sup>12</sup></label>Department of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Japan</aff>
                <aff id="aff13"><label><sup>13</sup></label>Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea</aff>
                <aff id="aff14"><label><sup>14</sup></label>Department of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain</aff>
                <aff id="aff15"><label><sup>15</sup></label>Individualized Medicine Application and Research Center and Department of Medical Oncology, Ege University, Izmir, Turkey</aff>
                <aff id="aff16"><label><sup>16</sup></label>Merck &amp; Co, Inc, Rahway, NJ</aff>
                <aff id="aff17"><label><sup>17</sup></label>Eisai Inc, Nutley, NJ</aff>
                <aff id="aff18"><label><sup>18</sup></label>Eisai Ltd, Hatfield, United Kingdom</aff>
                <aff id="aff19"><label><sup>19</sup></label>MSD Switzerland, Zurich, Switzerland</aff>
                <aff id="aff20"><label><sup>20</sup></label>Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Vicky Makker, MD, Memorial Sloan Kettering Cancer Center, 300 East 66th St, New York, NY 10065; e-mail: <email>makkerv@mskcc.org</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>1</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>41</volume>
              <issue>16</issue>
              <fpage>2904</fpage>
              <lpage>2910</lpage>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>15</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>¬© 2023 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="jco-41-2904.pdf"/>
              <related-object source-id-type="registry-name" document-id="NCT03517449" document-id-type="clinical-trial-number" source-type="clinical-trials-registry" source-id="ClinicalTrials.gov" id="d64e384"/>
              <abstract>
                <p><italic toggle="yes">Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</italic> JCO <italic toggle="yes">or elsewhere, for which the primary end point has already been reported.</italic></p>
                <p>We report the final prespecified analysis for overall survival (OS), along with updated progression-free survival (PFS) and objective response rate (ORR), and safety from the open-label, randomized, phase III Study 309/KEYNOTE-775. In total, 827 patients with advanced, recurrent, or metastatic endometrial cancer (EC) were randomly assigned to receive lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously once every 3 weeks (n = 411) or chemotherapy of the treating physician's choice (doxorubicin 60 mg/m<sup>2</sup> intravenously once every 3 weeks or paclitaxel 80 mg/m<sup>2</sup> intravenously once weekly [3 weeks on; 1 week off] [n = 416]). Efficacy was reported for patients with mismatch repair proficient (pMMR) tumors and all-comers, and by subgroups (histology, prior therapy, MMR status). Updated safety was also reported.</p>
                <p>Lenvatinib plus pembrolizumab showed benefits in OS (pMMR HR, 0.70; 95% CI, 0.58 to 0.83; all-comer HR, 0.65; 95% CI, 0.55 to 0.77), PFS (pMMR HR, 0.60; 95% CI, 0.50 to 0.72; all-comer HR, 0.56; 95% CI, 0.48 to 0.66), and ORR (pMMR patients, 32.4% <italic toggle="yes">v</italic> 15.1%; all-comers, 33.8% <italic toggle="yes">v</italic> 14.7%) versus chemotherapy. OS, PFS, and ORR favored lenvatinib plus pembrolizumab in all subgroups of interest. No new safety signals were observed. Lenvatinib plus pembrolizumab continued to show improved efficacy versus chemotherapy and manageable safety in patients with previously treated advanced EC.</p>
              </abstract>
              <counts>
                <fig-count count="2"/>
                <table-count count="2"/>
                <equation-count count="0"/>
                <ref-count count="15"/>
                <page-count count="0"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>Approximately 10%‚Äì15% of patients with endometrial cancer (EC) have advanced disease at diagnosis,<sup><xref rid="b1" ref-type="bibr">1</xref></sup> and the 5-year relative survival rate among patients with distant metastases is approximately 20%.<sup><xref rid="b2" ref-type="bibr">2</xref></sup> The single-arm phase Ib/II Study 111/KEYNOTE-146 that evaluated lenvatinib plus pembrolizumab in patients with previously treated advanced endometrial carcinoma showed notable efficacy and manageable safety, irrespective of mismatch repair (MMR) status.<sup><xref rid="b3" ref-type="bibr">3</xref></sup> At the primary analysis, the confirmatory phase III Study 309/KEYNOTE-775 (ClinicalTrials.gov identifier: <ext-link xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT03517449" ext-link-type="uri">NCT03517449</ext-link>) demonstrated statistically significant, clinically meaningful improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) versus chemotherapy (doxorubicin or paclitaxel) in previously treated advanced EC (both in patients with mismatch repair proficient [pMMR] tumors and in all-comer patients) and no new safety signals.<sup><xref rid="b4" ref-type="bibr">4</xref></sup></p>
              <p>We report the final prespecified OS analysis for Study 309/KEYNOTE-775. Updated PFS and ORR, efficacy by subgroups (histology, prior therapy, and MMR status), and updated safety are also reported.</p>
            </sec>
            <sec sec-type="methods">
              <title>METHODS</title>
              <p>Inclusion/exclusion criteria and procedures for this open-label, phase III trial were previously published<sup><xref rid="b4" ref-type="bibr">4</xref></sup> (Data Supplement [online only] for summary).</p>
              <p>We report final prespecified OS and updated PFS and ORR (blinded independent central review per RECIST v1.1) in pMMR and all-comer patients and safety in all-comers. Additionally, we report PFS, OS, and ORR by prespecified subgroups (histology [endometrioid or nonendometrioid], prior therapy [1, 2, ‚â• 3 lines], and MMR status). Efficacy and safety were assessed in all randomly assigned patients and all patients who received ‚â•1 dose of study treatment, respectively.</p>
              <p>The nonparametric Kaplan-Meier method was used to estimate survival curves for PFS and OS, and a stratified Cox proportional hazards model with Efron's method of handling ties was used to assess hazard ratios (HRs). The stratified Miettinen and Nurminen's method was used to assess differences in ORR. Differences in percentages of patients with an objective response and the 95% CIs (not adjusted for multiplicity) with strata weighting according to sample size were reported. For OS, PFS, and ORR analyses, the stratification factors used for random assignment were applied. PFS and OS subgroup analyses were conducted using an unstratified Cox model, and ORR subgroup analyses were conducted using the unstratified Miettinen and Nurminen's method (except pMMR analyses, which used the same stratified methods used for primary analyses). All analyses are descriptive.</p>
              <p>This study was approved by each research site's institutional review board or independent ethics committee. All patients provided written, informed consent.</p>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec sec-type="subjects">
                <title>Patients and Treatments</title>
                <p>Eight hundred twenty-seven patients were randomly assigned to the lenvatinib plus pembrolizumab (n = 411) or chemotherapy (n = 416) arms; 697 patients had pMMR tumors and 130 had mismatch repair deficient (dMMR) tumors. Data cutoff occurred on March 1, 2022 (&gt;16 months of additional follow-up from the primary analysis). The median follow-up was 18.7 months in the lenvatinib plus pembrolizumab arm and 12.2 months in the chemotherapy arm (14.7 months overall). Patient disposition is summarized in Data Supplement.</p>
                <p>Baseline characteristics were balanced between the treatment groups (Table <xref rid="tbl1" ref-type="table">1</xref>), and characteristics of dMMR patients were generally consistent with those of the pMMR and all-comer populations (Data Supplement). Of all randomly assigned patients, 84.2% in the lenvatinib plus pembrolizumab arm and 84.4% in the chemotherapy arm had confirmed pMMR tumors. Treatment history is summarized in the Data Supplement.</p>
                <table-wrap position="float" id="tbl1">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Baseline Demographic and Clinical Characteristics: pMMR and All-Comer Populations</p>
                  </caption>
                  <graphic xlink:href="jco-41-2904-g001" position="float"/>
                </table-wrap>
              </sec>
              <sec>
                <title>Efficacy</title>
                <p>OS in the pMMR population was longer in the lenvatinib plus pembrolizumab arm (median, 18.0 months; 95% CI, 14.9 to 20.5) versus the chemotherapy arm (median, 12.2 months; 95% CI, 11.0 to 14.1; HR, 0.70; 95% CI, 0.58 to 0.83; Fig <xref rid="fig1" ref-type="fig">1</xref>A), with similar results observed in all comers (lenvatinib plus pembrolizumab median, 18.7 months; 95% CI, 15.6 to 21.3; chemotherapy median, 11.9 months; 95% CI, 10.7 to 13.3; HR, 0.65; 95% CI, 0.55 to 0.77; Fig <xref rid="fig1" ref-type="fig">1</xref>B). Similar results were observed when excluding patients in the chemotherapy arm who received subsequent lenvatinib plus pembrolizumab or those who received any subsequent PD-1/PD-L1 checkpoint inhibitor therapy (Data Supplement). PFS in the pMMR population was longer in the lenvatinib plus pembrolizumab arm (median, 6.7 months; 95% CI, 5.6 to 7.4) versus the chemotherapy arm (median, 3.8 months; 95% CI, 3.6 to 5.0; HR, 0.60; 95% CI, 0.50 to 0.72; Fig <xref rid="fig1" ref-type="fig">1</xref>C). Similar results were seen in all-comer patients (lenvatinib plus pembrolizumab median, 7.3 months; 95% CI, 5.7 to 7.6; chemotherapy median, 3.8 months; 95% CI, 3.6 to 4.2; HR, 0.56; 95% CI, 0.48 to 0.66; Fig <xref rid="fig1" ref-type="fig">1</xref>D).</p>
                <fig position="float" id="fig1" fig-type="figure">
                  <label>FIG 1.</label>
                  <caption>
                    <p>OS: (A) pMMR population and (B) all-comer population. PFS<sup>a</sup>: (C) pMMR population and (D) all-comer population. <sup>a</sup>Assessed by blinded independent central review; per RECIST v1.1. HR, hazard ratio; OS, overall survival; PFS, progression-free survival; pMMR, mismatch repair proficient.</p>
                  </caption>
                  <graphic xlink:href="jco-41-2904-g002" position="float"/>
                </fig>
                <p>The percentage of patients with pMMR tumors with a confirmed objective response was higher with lenvatinib plus pembrolizumab (32.4%) than with chemotherapy (15.1%), with 5.8% and 2.6% of patients, respectively, achieving complete responses (CRs); the median duration of response (DOR) was 9.3 months (range, 1.6+ to 39.5+) with lenvatinib plus pembrolizumab versus 5.7 months (range, 0.0+ to 37.1+) with chemotherapy (Data Supplement). Similar results were observed in the all-comer population (confirmed ORR, 33.8% <italic toggle="yes">v</italic> 14.7%); 7.5% and 2.6% of patients had CRs, respectively; the median DOR was 12.9 months (range, 1.6 + to 39.5+) with lenvatinib plus pembrolizumab and 5.7 months (range, 0.0+ to 37.1+) with chemotherapy (Data Supplement). More patients experienced tumor shrinkage in the lenvatinib plus pembrolizumab arm versus the chemotherapy arm (Data Supplement). Additionally, clinically meaningful improvements across efficacy end points were observed with lenvatinib plus pembrolizumab in the dMMR population (Data Supplement).</p>
                <p>Overall, PFS, OS, and ORR in the pMMR and all-comer populations favored lenvatinib plus pembrolizumab in all subgroups of interest (Data Supplement). Of note, the majority of patients who received lenvatinib plus pembrolizumab experienced tumor shrinkage regardless of histology (Data Supplement).</p>
              </sec>
              <sec>
                <title>Safety</title>
                <p>Seven hundred ninety-four patients treated with lenvatinib plus pembrolizumab (n = 406) or chemotherapy (n = 388) were included in the safety analysis population. Drug exposure is summarized in the Data Supplement; dose modifications and discontinuations are summarized in the Data Supplement.</p>
                <p>Any-grade treatment-emergent adverse events (TEAEs) occurred in 99.8% of patients who received lenvatinib plus pembrolizumab and 99.5% of patients who received chemotherapy. The most common TEAE in the lenvatinib plus pembrolizumab arm was hypertension (65.0%); the most common TEAE in the chemotherapy arm was anemia (48.7%) (Table <xref rid="tbl2" ref-type="table">2</xref>). Grade ‚â• 3 TEAEs occurred in 90.1% of patients receiving lenvatinib plus pembrolizumab and 73.7% of patients receiving chemotherapy (grade 5 TEAEs occurred in 6.4% and 5.2% of patients, respectively; Table <xref rid="tbl2" ref-type="table">2</xref>). Concomitant medications for adverse events (AEs) in patients who received lenvatinib plus pembrolizumab are summarized in the Data Supplement. Serious AEs are summarized in the Data Supplement. Treatment-related AEs are summarized in the Data Supplement. AEs of special interest and clinically significant AEs are summarized in the Data Supplement.</p>
                <table-wrap position="float" id="tbl2">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>TEAEs in Patients Who Received Study Treatment</p>
                  </caption>
                  <graphic xlink:href="jco-41-2904-g003" position="float"/>
                </table-wrap>
              </sec>
              <sec>
                <title>Subsequent Therapy</title>
                <p>Subsequent therapies are summarized in the Data Supplement. PFS on next-line therapy in pMMR and all-comer populations favored lenvatinib plus pembrolizumab (Data Supplement).</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>With extended follow-up, lenvatinib plus pembrolizumab continued to show considerable efficacy benefit versus chemotherapy. The results were consistent with the primary analysis (Data Supplement), highlighting the durable and robust treatment benefit of lenvatinib plus pembrolizumab. OS benefit was maintained despite 10.0% of the pMMR population and 8.7% of all-comers in the chemotherapy arm receiving subsequent lenvatinib plus pembrolizumab. Efficacy results in the chemotherapy arm were comparable with findings from other phase III trials investigating second-line or later treatments.<sup><xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b6" ref-type="bibr">6</xref></sup></p>
              <p>No new safety signals were observed, and safety results were comparable with those reported at the primary analysis.<sup><xref rid="b4" ref-type="bibr">4</xref></sup> Safety results were also comparable with those reported for lenvatinib plus pembrolizumab in the earlier Study 111/KEYNOTE-146<sup><xref rid="b3" ref-type="bibr">3</xref></sup> and to established AE profiles of each agent in EC.<sup><xref rid="b7" ref-type="bibr">7</xref>-<xref rid="b10" ref-type="bibr">10</xref></sup> Similarly, safety results were also comparable to each agent and the combination in other tumor types.<sup><xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b11" ref-type="bibr">11</xref>-<xref rid="b15" ref-type="bibr">15</xref></sup></p>
              <p>The results further support lenvatinib plus pembrolizumab as standard therapy in patients with previously treated advanced EC.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>Medical writing support was provided by Irene Minkina, PhD, of Oxford PharmaGenesis Inc, Newtown, PA, with funding by Eisai Inc, Nutley, NJ, and Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co, Inc, Rahway, NJ. We thank Erin Jensen (Merck &amp; Co, Inc, Rahway, NJ) for her contributions to this work.</p>
            </ack>
            <fn-group content-type="disclaimer">
              <title>DISCLAIMER</title>
              <fn specific-use="con" fn-type="con">
                <p>Both funders contributed to the study design; collection, analysis, and interpretation of data; and preparation, review, and approval of the manuscript. The authors had full access to the data and control of the final approval and decision to submit the manuscript for publication.</p>
              </fn>
            </fn-group>
            <fn-group content-type="presented-at">
              <title>PRIOR PRESENTATION</title>
              <fn specific-use="presented-at" fn-type="presented-at">
                <p>Presented in part at the European Society for Medical Oncology Congress, Paris, France, September 9-13, 2022; the Annual Global Meeting of the International Gynecologic Cancer Society, New York, NY, September 29-October 1, 2022; and the European Congress on Gynecologic Oncology, Berlin, Germany, October 27-30, 2022.</p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn specific-use="supported-by" fn-type="supported-by">
                <p>This study was sponsored by Eisai Inc, Nutley, NJ, and Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co, Inc, Rahway, NJ.</p>
              </fn>
            </fn-group>
            <fn-group content-type="trial">
              <title>CLINICAL TRIAL INFORMATION</title>
              <fn specific-use="trial" fn-type="other">
                <p>
                  <ext-link xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT03517449" ext-link-type="uri">NCT03517449</ext-link>
                </p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>DATA SHARING STATEMENT</title>
              <p>The data will not be available for sharing at this time because the data are commercially confidential. However, Eisai Inc will consider written requests to share the data on a case-by-case basis.</p>
            </sec>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Antonio Casado Herr√°ez, Kan Yonemori, Eva M. Guerra Alia, Robert Orlowski, Gianmaria Barresi</p>
              <p><bold>Financial support:</bold> Kan Yonemori</p>
              <p><bold>Administrative support:</bold> Kan Yonemori</p>
              <p><bold>Provision of study materials or patients:</bold> Nicoletta Colombo, Antonio Casado Herr√°ez, Bradley J. Monk, Helen Mackay, Alessandro D. Santin, David S. Miller, Sally Baron-Hay, Isabelle Ray-Coquard, Kan Yonemori, Yong Man Kim, Eva M. Guerra Alia, Ulus A. Sanli</p>
              <p><bold>Collection and assembly of data:</bold> Vicky Makker, Antonio Casado Herr√°ez, Bradley J. Monk, Helen Mackay, David S. Miller, Richard G. Moore, Sally Baron-Hay, Isabelle Ray-Coquard, Kimio Ushijima, Yong Man Kim, Eva M. Guerra Alia, Ulus A. Sanli, Robert Orlowski, Jodi McKenzie, Gianmaria Barresi, Domenica Lorusso</p>
              <p><bold>Data analysis and interpretation:</bold> Nicoletta Colombo, Antonio Casado Herr√°ez, Bradley J. Monk, Helen Mackay, Alessandro D. Santin, David S. Miller, Richard G. Moore, Isabelle Ray-Coquard, Kan Yonemori, Eva M. Guerra Alia, Steven Bird, Robert Orlowski, Jodi McKenzie, Chinyere Okpara, Gianmaria Barresi</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="COI-statement">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="https://ascopubs.org/jco/authors/author-center" ext-link-type="uri">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p>
                <fn-group content-type="COI-statement">
                  <fn id="con1" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Kimio Ushijima</bold>
                    </p>
                    <p><bold>Honoraria:</bold> AstarZenca, Chugai Pharma, Takeda, MSD, Kaken Pharmaceutical, Kyowa Kirin International, Mochida Pharmaceutical Co. Ltd, Asuka Seiyaku, Zeria Pharmaceutical, Sanofi</p>
                    <p><bold>Research Funding:</bold> AstarZenca (Inst), Chugai Pharma (Inst), Takeda (Inst), Kaken Pharmaceutical (Inst), Nippon Kayaku (Inst), Mochida Pharmaceutical Co. Ltd (Inst), Taiho Pharmaceutical (Inst), Eisai (Inst), Ono Pharmaceutical (Inst), MSD (Inst)</p>
                  </fn>
                  <fn id="con2" specific-use="other" fn-type="other">
                    <p>
                      <bold>Jodi McKenzie</bold>
                    </p>
                    <p><bold>Employment:</bold> Eisai</p>
                  </fn>
                  <fn id="con3" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Vicky Makker</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Eisai, Merck, Karyopharm Therapeutics, Takeda, ArQule, IBM, GlaxoSmithKline, Clovis Oncology, Faeth Therapeutics, Novartis, Duality, ITeos Therapeutics, Kartos Therapeutics, Lilly</p>
                    <p><bold>Research Funding:</bold> Lilly (Inst), AstraZeneca (Inst), Eisai (Inst), Merck (Inst), Bristol Myers Squibb (Inst), Karyopharm Therapeutics (Inst), Takeda (Inst), Clovis Oncology (Inst), Bayer (Inst), Zymeworks (Inst), Duality (Inst), Faeth Therapeutics (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Eisai, Merck, Karyopharm Therapeutics</p>
                    <p><bold>Other Relationship:</bold> IBM</p>
                  </fn>
                  <fn id="con4" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Richard Moore</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Fujirebio Diagnostics, GlaxoSmithKline</p>
                    <p><bold>Consulting or Advisory Role:</bold> Fujirebio Diagnostics</p>
                    <p><bold>Research Funding:</bold> Angle</p>
                  </fn>
                  <fn id="con5" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Alessandro Santin</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Merck, Tesaro, R-Pharm</p>
                    <p><bold>Research Funding:</bold> Tesaro (Inst), Merck (Inst), Boehringer Ingelheim (Inst), Gilead Sciences (Inst), Puma Biotechnology (Inst), Genentech/Roche (Inst), Genentech/Roche (Inst), R-Pharm (Inst), Immunomedics (Inst), Verastem (Inst)</p>
                  </fn>
                  <fn id="con6" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Domenica Lorusso</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> PharmaMar, AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, Genmab, Seattle Genetics, Immunogen, Oncoinvest, Corcept Therapeutics, Sutro Biopharma, Novartis</p>
                    <p><bold>Speakers' Bureau:</bold> AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, PharmaMar, ImmunoGen, Seattle Genetics, Genmab</p>
                    <p><bold>Research Funding:</bold> PharmaMar (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), Genmab (Inst), Seattle Genetics (Inst), Immunogen (Inst), Incyte (Inst), Novartis (Inst), Roche (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca, Clovis Oncology, GlaxoSmithKline</p>
                    <p><bold>Uncompensated Relationships:</bold> Gynecological Cancer InterGroup</p>
                  </fn>
                  <fn id="con7" specific-use="other" fn-type="other">
                    <p>
                      <bold>Helen Mackay</bold>
                    </p>
                    <p><bold>Honoraria:</bold> AstraZeneca, GlaxoSmithKline</p>
                    <p><bold>Consulting or Advisory Role:</bold> Merck, Eisai, GlaxoSmithKline</p>
                  </fn>
                  <fn id="con8" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Kan Yonemori</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Eisai, Pfizer, AstraZeneca, Novartis, Taiho Pharmaceutical, Lilly Japan, Daiichi Sankyo/Astra Zeneca, Takeda, Fujifilm, Ono Pharmaceutical, Chugai Pharma, MSD Oncology</p>
                    <p><bold>Consulting or Advisory Role:</bold> Chugai Pharma, Ono Pharmaceutical, Novartis, Eisai, OncXerna Therapeutics</p>
                    <p><bold>Research Funding:</bold> Ono Pharmaceutical (Inst), MSD (Inst), Daiichi Sankyo/Astra Zeneca (Inst), AstraZeneca/MedImmune (Inst), Taiho Pharmaceutical (Inst), Pfizer (Inst), Novartis (Inst), Takeda (Inst), Takeda (Inst), Takeda (Inst), Chugai Pharma (Inst), Sanofi (Inst), Seattle Genetics (Inst), Eisai (Inst), Lilly (Inst), Genmab (Inst), Boehringer Ingelheim (Inst), Kyowa Hakko Kirrin (Inst), Haihe Pharmaceutical (Inst), Nihonkayaku (Inst)</p>
                  </fn>
                  <fn id="con9" specific-use="other" fn-type="other">
                    <p>
                      <bold>Gianmaria Barresi</bold>
                    </p>
                    <p><bold>Employment:</bold> MSD</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> MSD</p>
                  </fn>
                  <fn id="con10" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Antonio Casado Herraez</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Roche, PharmaMar, Eisai, Merck Sharp &amp; Dohme, Eisai</p>
                    <p><bold>Research Funding:</bold> Pharmamar (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Pharmamar, Roche, Lilly, PharmaMar</p>
                    <p><bold>Other Relationship:</bold> Lilly (Inst)</p>
                  </fn>
                  <fn id="con11" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Isabelle Ray-Coquard</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Roche, PharmaMar, AstraZeneca, Clovis Oncology, Tesaro, MSD Oncology, Genmab, AbbVie, Pfizer, Bristol Myers Squibb, GlaxoSmithKline, DECIPHERA, MERSANA, Amgen, Advaxis, OxOnc, Seattle Genetics, Macrogenics, Agenus, Sutro Biopharma, Novartis, Daiichi Sankyo</p>
                    <p><bold>Consulting or Advisory Role:</bold> Pfizer, AbbVie, Genmab, Roche, AstraZeneca, Tesaro, Clovis Oncology, PharmaMar, MSD Oncology, Bristol Myers Squibb, Deciphera, Mersana, GlaxoSmithKline, Agenus, Macrogenics, Seattle Genetics, BMS, Novartis, Novocure, Ose pharma, Daichi, Sutro Biopharma, Eisai, Blueprint Medicines</p>
                    <p><bold>Research Funding:</bold> MSD Oncology, BMS, Roche/Genentech (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Roche, AstraZeneca, Tesaro, PharmaMar, GlaxoSmithKline, Clovis Oncology, Clovis Oncology, BMS, Advaxis</p>
                    <p><bold>Uncompensated Relationships:</bold> Arcagy-Gineco, French National Cancer Institute (INCA), Italian Health Authorities, German Health Authorities, Belgium Health Authorities</p>
                  </fn>
                  <fn id="con12" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Robert Orlowski</bold>
                    </p>
                    <p><bold>Employment:</bold> Merck Sharp &amp; Dohme</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Merck Sharp &amp; Dohme, OncoSec, Nektar, Bluebird Bio, 270 bio, Bristol Myers Squibb</p>
                    <p><bold>Research Funding:</bold> Merck Sharp &amp; Dohme</p>
                  </fn>
                  <fn id="con13" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>Bradley Monk</bold>
                    </p>
                    <p><bold>Leadership:</bold> US Oncology</p>
                    <p><bold>Honoraria:</bold> Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, TESARO/GSK, Vascular Biogenics, GOG Foundation, Elevar Therapeutics, Novocure, Gradalis, Karyopharm Therapeutics, Bayer, EMD Serono/Merck, Macrogenics, Sorrento Therapeutics, US Oncology, Myriad Pharmaceuticals, Novartis, OncoC4, Pieris Pharmaceuticals</p>
                    <p><bold>Consulting or Advisory Role:</bold> Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana, Myriad Pharmaceuticals, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, TESARO/GSK, Vascular Biogenics, Gradalis, Karyopharm Therapeutics, Sorrento Therapeutics, Novocure, Bayer, Elevar Therapeutics, EMD Serono/Merck, Gradalis, US Oncology, Novartis, Pieris Pharmaceuticals, OncoC4</p>
                    <p><bold>Speakers' Bureau:</bold> Roche/Genentech, AstraZeneca, Clovis Oncology, Eisai, TESARO/GSK, Merck</p>
                    <p><bold>Research Funding:</bold> Novartis (Inst), Amgen (Inst), Genentech (Inst), Lilly (Inst), Janssen (Inst), Array BioPharma (Inst), Tesaro (Inst), Morphotek (Inst), Pfizer (Inst), Advaxis (Inst), AstraZeneca (Inst), Immunogen (Inst), Regeneron (Inst), Nucana (Inst)</p>
                  </fn>
                  <fn id="con14" specific-use="other" fn-type="other">
                    <p>
                      <bold>Chinyere Okpara</bold>
                    </p>
                    <p><bold>Employment:</bold> Eisai</p>
                  </fn>
                  <fn id="con15" specific-use="other" fn-type="other">
                    <p>
                      <bold>Nicoletta Colombo</bold>
                    </p>
                    <p><bold>Employment:</bold> Sarepta Therapeutics</p>
                    <p><bold>Honoraria:</bold> Roche/Genentech, AstraZeneca, GlaxoSmithKline, MSD Oncology, Clovis Oncology, Pfizer, Amgen, Immunogen, Novartis, Pfizer, mersana, Eisai, Advaxis, Nuvation Bio</p>
                    <p><bold>Consulting or Advisory Role:</bold> Roche/Genentech, AstraZeneca, Clovis Oncology, Pfizer, MSD Oncology, GlaxoSmithKline, Immunogen, Pfizer, mersana, Eisai, Advaxis, Nuvation Bio</p>
                  </fn>
                  <fn id="con16" specific-use="other" fn-type="other">
                    <p>
                      <bold>Sally Baron-Hay</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Merck Sharpe and Doehme, AstraZeneca, Novartis, Eisai, GlaxoSmithKline, Pfizer, Roche</p>
                    <p><bold>Speakers' Bureau:</bold> MSD Oncology</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Gilead Sciences, MSD Oncology</p>
                  </fn>
                  <fn id="con17" specific-use="other" fn-type="other">
                    <p>
                      <bold>Steven Bird</bold>
                    </p>
                    <p><bold>Employment:</bold> Merck Sharp &amp; Dohme</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Merck Sharp &amp; Dohme</p>
                  </fn>
                  <fn id="con18" specific-use="financial-disclosure" fn-type="financial-disclosure">
                    <p>
                      <bold>David Miller</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Eisai, AstraZeneca, Karyopharm Therapeutics, Incyte, Merck Sharp &amp; Dohme, Asymmetric Therapeutics, Boston Biomedical Research Institute, Tarveda Therapeutics, Myriad Genetic Laboratories, GlaxoSmithKline, AbbVie, Incyte, EMD Serono, Seattle Genetics, Clinical Education Alliance, Eisai, GlaxoSmithKline, ITeos Therapeutics, Novocure, Novartis, Immunogen, Agenus</p>
                    <p><bold>Research Funding:</bold> US Biotest (Inst), Advenchen Laboratories (Inst), Tesaro (Inst), Xenetic Biosciences (Inst), Advaxis (Inst), Janssen (Inst), Aeterna Zentaris (Inst), TRACON Pharma (Inst), Pfizer (Inst), Immunogen (Inst), Mateon Therapeutics (Inst), Merck Sharp &amp; Dohme (Inst), AstraZeneca (Inst), Millenium Pharamceuticals (Inst), Aprea AB (Inst), Regeneron (Inst), NVision (Inst), Novartis (Inst), Syros Pharmaceuticals (Inst), Karyopharm Therapeutics (Inst), Agenus (Inst), Akeso Biopharma (Inst), EMD Serono, Incyte (Inst), Leap Therapeutics</p>
                  </fn>
                  <fn id="con19" specific-use="other" fn-type="other">
                    <p>
                      <bold>Eva Guerra</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> AstraZeneca-MSD, Clovis Oncology, GlaxoSmithKline/Tesaro, GlaxoSmithKline/Tesaro, PharmaMar, Roche</p>
                    <p><bold>Speakers' Bureau:</bold> AstraZeneca-MSD, PharmaMar, Roche, GlaxoSmithKline/Tesaro</p>
                    <p><bold>Expert Testimony:</bold> AstraZeneca-MSD, GlaxoSmithKline/Tesaro, Roche, PharmaMar, Clovis Oncology</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Roche, GlaxoSmithKline/Tesaro</p>
                  </fn>
                  <fn id="con20" specific-use="conflict" fn-type="COI-statement">
                    <p>
                      <bold>Domenica Lorusso</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> PharmaMar, AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, Genmab, Seattle Genetics, Immunogen, Oncoinvest, Corcept Therapeutics, Sutro Biopharma, Novartis</p>
                    <p><bold>Speakers' Bureau:</bold> AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, PharmaMar, ImmunoGen, Seattle Genetics, Genmab</p>
                    <p><bold>Research Funding:</bold> PharmaMar (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), Genmab (Inst), Seattle Genetics (Inst), Immunogen (Inst), Incyte (Inst), Novartis (Inst), Roche (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca, Clovis Oncology, GlaxoSmithKline</p>
                    <p><bold>Uncompensated Relationships:</bold> Gynecological Cancer InterGroup</p>
                    <p>No other potential conflicts of interest were reported.</p>
                  </fn>
                </fn-group>
              </sec>
            </sec>
            <notes>
              <fn-group content-type="COI-statement">
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Kimio Ushijima</bold>
                  </p>
                  <p><bold>Honoraria:</bold> AstarZenca, Chugai Pharma, Takeda, MSD, Kaken Pharmaceutical, Kyowa Kirin International, Mochida Pharmaceutical Co. Ltd, Asuka Seiyaku, Zeria Pharmaceutical, Sanofi</p>
                  <p><bold>Research Funding:</bold> AstarZenca (Inst), Chugai Pharma (Inst), Takeda (Inst), Kaken Pharmaceutical (Inst), Nippon Kayaku (Inst), Mochida Pharmaceutical Co. Ltd (Inst), Taiho Pharmaceutical (Inst), Eisai (Inst), Ono Pharmaceutical (Inst), MSD (Inst)</p>
                </fn>
                <fn specific-use="other" fn-type="other">
                  <p>
                    <bold>Jodi McKenzie</bold>
                  </p>
                  <p><bold>Employment:</bold> Eisai</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Vicky Makker</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Eisai, Merck, Karyopharm Therapeutics, Takeda, ArQule, IBM, GlaxoSmithKline, Clovis Oncology, Faeth Therapeutics, Novartis, Duality, ITeos Therapeutics, Kartos Therapeutics, Lilly</p>
                  <p><bold>Research Funding:</bold> Lilly (Inst), AstraZeneca (Inst), Eisai (Inst), Merck (Inst), Bristol Myers Squibb (Inst), Karyopharm Therapeutics (Inst), Takeda (Inst), Clovis Oncology (Inst), Bayer (Inst), Zymeworks (Inst), Duality (Inst), Faeth Therapeutics (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Eisai, Merck, Karyopharm Therapeutics</p>
                  <p><bold>Other Relationship:</bold> IBM</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Richard Moore</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Fujirebio Diagnostics, GlaxoSmithKline</p>
                  <p><bold>Consulting or Advisory Role:</bold> Fujirebio Diagnostics</p>
                  <p><bold>Research Funding:</bold> Angle</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Alessandro Santin</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Merck, Tesaro, R-Pharm</p>
                  <p><bold>Research Funding:</bold> Tesaro (Inst), Merck (Inst), Boehringer Ingelheim (Inst), Gilead Sciences (Inst), Puma Biotechnology (Inst), Genentech/Roche (Inst), Genentech/Roche (Inst), R-Pharm (Inst), Immunomedics (Inst), Verastem (Inst)</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Domenica Lorusso</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> PharmaMar, AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, Genmab, Seattle Genetics, Immunogen, Oncoinvest, Corcept Therapeutics, Sutro Biopharma, Novartis</p>
                  <p><bold>Speakers' Bureau:</bold> AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, PharmaMar, ImmunoGen, Seattle Genetics, Genmab</p>
                  <p><bold>Research Funding:</bold> PharmaMar (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), Genmab (Inst), Seattle Genetics (Inst), Immunogen (Inst), Incyte (Inst), Novartis (Inst), Roche (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca, Clovis Oncology, GlaxoSmithKline</p>
                  <p><bold>Uncompensated Relationships:</bold> Gynecological Cancer InterGroup</p>
                </fn>
                <fn specific-use="other" fn-type="other">
                  <p>
                    <bold>Helen Mackay</bold>
                  </p>
                  <p><bold>Honoraria:</bold> AstraZeneca, GlaxoSmithKline</p>
                  <p><bold>Consulting or Advisory Role:</bold> Merck, Eisai, GlaxoSmithKline</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Kan Yonemori</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Eisai, Pfizer, AstraZeneca, Novartis, Taiho Pharmaceutical, Lilly Japan, Daiichi Sankyo/Astra Zeneca, Takeda, Fujifilm, Ono Pharmaceutical, Chugai Pharma, MSD Oncology</p>
                  <p><bold>Consulting or Advisory Role:</bold> Chugai Pharma, Ono Pharmaceutical, Novartis, Eisai, OncXerna Therapeutics</p>
                  <p><bold>Research Funding:</bold> Ono Pharmaceutical (Inst), MSD (Inst), Daiichi Sankyo/Astra Zeneca (Inst), AstraZeneca/MedImmune (Inst), Taiho Pharmaceutical (Inst), Pfizer (Inst), Novartis (Inst), Takeda (Inst), Takeda (Inst), Takeda (Inst), Chugai Pharma (Inst), Sanofi (Inst), Seattle Genetics (Inst), Eisai (Inst), Lilly (Inst), Genmab (Inst), Boehringer Ingelheim (Inst), Kyowa Hakko Kirrin (Inst), Haihe Pharmaceutical (Inst), Nihonkayaku (Inst)</p>
                </fn>
                <fn specific-use="other" fn-type="other">
                  <p>
                    <bold>Gianmaria Barresi</bold>
                  </p>
                  <p><bold>Employment:</bold> MSD</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> MSD</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Antonio Casado Herraez</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Roche, PharmaMar, Eisai, Merck Sharp &amp; Dohme, Eisai</p>
                  <p><bold>Research Funding:</bold> Pharmamar (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Pharmamar, Roche, Lilly, PharmaMar</p>
                  <p><bold>Other Relationship:</bold> Lilly (Inst)</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Isabelle Ray-Coquard</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Roche, PharmaMar, AstraZeneca, Clovis Oncology, Tesaro, MSD Oncology, Genmab, AbbVie, Pfizer, Bristol Myers Squibb, GlaxoSmithKline, DECIPHERA, MERSANA, Amgen, Advaxis, OxOnc, Seattle Genetics, Macrogenics, Agenus, Sutro Biopharma, Novartis, Daiichi Sankyo</p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer, AbbVie, Genmab, Roche, AstraZeneca, Tesaro, Clovis Oncology, PharmaMar, MSD Oncology, Bristol Myers Squibb, Deciphera, Mersana, GlaxoSmithKline, Agenus, Macrogenics, Seattle Genetics, BMS, Novartis, Novocure, Ose pharma, Daichi, Sutro Biopharma, Eisai, Blueprint Medicines</p>
                  <p><bold>Research Funding:</bold> MSD Oncology, BMS, Roche/Genentech (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Roche, AstraZeneca, Tesaro, PharmaMar, GlaxoSmithKline, Clovis Oncology, Clovis Oncology, BMS, Advaxis</p>
                  <p><bold>Uncompensated Relationships:</bold> Arcagy-Gineco, French National Cancer Institute (INCA), Italian Health Authorities, German Health Authorities, Belgium Health Authorities</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Robert Orlowski</bold>
                  </p>
                  <p><bold>Employment:</bold> Merck Sharp &amp; Dohme</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Merck Sharp &amp; Dohme, OncoSec, Nektar, Bluebird Bio, 270 bio, Bristol Myers Squibb</p>
                  <p><bold>Research Funding:</bold> Merck Sharp &amp; Dohme</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>Bradley Monk</bold>
                  </p>
                  <p><bold>Leadership:</bold> US Oncology</p>
                  <p><bold>Honoraria:</bold> Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, TESARO/GSK, Vascular Biogenics, GOG Foundation, Elevar Therapeutics, Novocure, Gradalis, Karyopharm Therapeutics, Bayer, EMD Serono/Merck, Macrogenics, Sorrento Therapeutics, US Oncology, Myriad Pharmaceuticals, Novartis, OncoC4, Pieris Pharmaceuticals</p>
                  <p><bold>Consulting or Advisory Role:</bold> Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana, Myriad Pharmaceuticals, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, TESARO/GSK, Vascular Biogenics, Gradalis, Karyopharm Therapeutics, Sorrento Therapeutics, Novocure, Bayer, Elevar Therapeutics, EMD Serono/Merck, Gradalis, US Oncology, Novartis, Pieris Pharmaceuticals, OncoC4</p>
                  <p><bold>Speakers' Bureau:</bold> Roche/Genentech, AstraZeneca, Clovis Oncology, Eisai, TESARO/GSK, Merck</p>
                  <p><bold>Research Funding:</bold> Novartis (Inst), Amgen (Inst), Genentech (Inst), Lilly (Inst), Janssen (Inst), Array BioPharma (Inst), Tesaro (Inst), Morphotek (Inst), Pfizer (Inst), Advaxis (Inst), AstraZeneca (Inst), Immunogen (Inst), Regeneron (Inst), Nucana (Inst)</p>
                </fn>
                <fn specific-use="other" fn-type="other">
                  <p>
                    <bold>Chinyere Okpara</bold>
                  </p>
                  <p><bold>Employment:</bold> Eisai</p>
                </fn>
                <fn specific-use="other" fn-type="other">
                  <p>
                    <bold>Nicoletta Colombo</bold>
                  </p>
                  <p><bold>Employment:</bold> Sarepta Therapeutics</p>
                  <p><bold>Honoraria:</bold> Roche/Genentech, AstraZeneca, GlaxoSmithKline, MSD Oncology, Clovis Oncology, Pfizer, Amgen, Immunogen, Novartis, Pfizer, mersana, Eisai, Advaxis, Nuvation Bio</p>
                  <p><bold>Consulting or Advisory Role:</bold> Roche/Genentech, AstraZeneca, Clovis Oncology, Pfizer, MSD Oncology, GlaxoSmithKline, Immunogen, Pfizer, mersana, Eisai, Advaxis, Nuvation Bio</p>
                </fn>
                <fn specific-use="other" fn-type="other">
                  <p>
                    <bold>Sally Baron-Hay</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Merck Sharpe and Doehme, AstraZeneca, Novartis, Eisai, GlaxoSmithKline, Pfizer, Roche</p>
                  <p><bold>Speakers' Bureau:</bold> MSD Oncology</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Gilead Sciences, MSD Oncology</p>
                </fn>
                <fn specific-use="other" fn-type="other">
                  <p>
                    <bold>Steven Bird</bold>
                  </p>
                  <p><bold>Employment:</bold> Merck Sharp &amp; Dohme</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Merck Sharp &amp; Dohme</p>
                </fn>
                <fn specific-use="financial-disclosure" fn-type="financial-disclosure">
                  <p>
                    <bold>David Miller</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Eisai, AstraZeneca, Karyopharm Therapeutics, Incyte, Merck Sharp &amp; Dohme, Asymmetric Therapeutics, Boston Biomedical Research Institute, Tarveda Therapeutics, Myriad Genetic Laboratories, GlaxoSmithKline, AbbVie, Incyte, EMD Serono, Seattle Genetics, Clinical Education Alliance, Eisai, GlaxoSmithKline, ITeos Therapeutics, Novocure, Novartis, Immunogen, Agenus</p>
                  <p><bold>Research Funding:</bold> US Biotest (Inst), Advenchen Laboratories (Inst), Tesaro (Inst), Xenetic Biosciences (Inst), Advaxis (Inst), Janssen (Inst), Aeterna Zentaris (Inst), TRACON Pharma (Inst), Pfizer (Inst), Immunogen (Inst), Mateon Therapeutics (Inst), Merck Sharp &amp; Dohme (Inst), AstraZeneca (Inst), Millenium Pharamceuticals (Inst), Aprea AB (Inst), Regeneron (Inst), NVision (Inst), Novartis (Inst), Syros Pharmaceuticals (Inst), Karyopharm Therapeutics (Inst), Agenus (Inst), Akeso Biopharma (Inst), EMD Serono, Incyte (Inst), Leap Therapeutics</p>
                </fn>
                <fn specific-use="other" fn-type="other">
                  <p>
                    <bold>Eva Guerra</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> AstraZeneca-MSD, Clovis Oncology, GlaxoSmithKline/Tesaro, GlaxoSmithKline/Tesaro, PharmaMar, Roche</p>
                  <p><bold>Speakers' Bureau:</bold> AstraZeneca-MSD, PharmaMar, Roche, GlaxoSmithKline/Tesaro</p>
                  <p><bold>Expert Testimony:</bold> AstraZeneca-MSD, GlaxoSmithKline/Tesaro, Roche, PharmaMar, Clovis Oncology</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Roche, GlaxoSmithKline/Tesaro</p>
                </fn>
                <fn specific-use="conflict" fn-type="COI-statement">
                  <p>
                    <bold>Domenica Lorusso</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> PharmaMar, AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, Genmab, Seattle Genetics, Immunogen, Oncoinvest, Corcept Therapeutics, Sutro Biopharma, Novartis</p>
                  <p><bold>Speakers' Bureau:</bold> AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, PharmaMar, ImmunoGen, Seattle Genetics, Genmab</p>
                  <p><bold>Research Funding:</bold> PharmaMar (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), Genmab (Inst), Seattle Genetics (Inst), Immunogen (Inst), Incyte (Inst), Novartis (Inst), Roche (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca, Clovis Oncology, GlaxoSmithKline</p>
                  <p><bold>Uncompensated Relationships:</bold> Gynecological Cancer InterGroup</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </notes>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>RA</given-names></name><name><surname>Fleming</surname><given-names>GF</given-names></name><name><surname>Lastra</surname><given-names>RR</given-names></name><etal/></person-group>: <article-title>Current recommendations and recent progress in endometrial cancer</article-title>. <source>CA: Cancer J Clin</source><volume>69</volume>:<fpage>258</fpage>-<lpage>279</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31074865</pub-id></mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>American Cancer Society</collab></person-group>: <source>Endometrial Cancer Early Detection, Diagnosis, and Staging</source>. <ext-link xlink:href="https://www.cancer.org/content/dam/CRC/PDF/Public/8611.00.pdf" ext-link-type="uri">https://www.cancer.org/content/dam/CRC/PDF/Public/8611.00.pdf</ext-link></mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makker</surname><given-names>V</given-names></name><name><surname>Taylor</surname><given-names>MH</given-names></name><name><surname>Aghajanian</surname><given-names>C</given-names></name><etal/></person-group>: <article-title>Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer</article-title>. <source>J Clin Oncol</source><volume>38</volume>:<fpage>2981</fpage>-<lpage>2992</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32167863</pub-id></mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makker</surname><given-names>V</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Casado Herr√°ez</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>Lenvatinib plus pembrolizumab for advanced endometrial cancer</article-title>. <source>N Engl J Med</source><volume>386</volume>:<fpage>437</fpage>-<lpage>448</lpage>, <year>2022</year><pub-id pub-id-type="pmid">35045221</pub-id></mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMeekin</surname><given-names>S</given-names></name><name><surname>Dizon</surname><given-names>D</given-names></name><name><surname>Barter</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer</article-title>. <source>Gynecol Oncol</source><volume>138</volume>:<fpage>18</fpage>-<lpage>23</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25925990</pub-id></mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DS</given-names></name><name><surname>Scambia</surname><given-names>G</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><etal/></person-group>: <article-title>ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155)</article-title>. <source>J Clin Oncol</source><volume>36</volume>:<year>2018</year> (<comment>supp; abstr 5503</comment>)</mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marabelle</surname><given-names>A</given-names></name><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><etal/></person-group>: <article-title>Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study</article-title>. <source>J Clin Oncol</source><volume>38</volume>:<fpage>1</fpage>-<lpage>10</lpage>, <year>2020</year><pub-id pub-id-type="pmid">31682550</pub-id></mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Berton-Rigaud</surname><given-names>D</given-names></name><etal/></person-group>: <article-title>Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study</article-title>. <source>J Clin Oncol</source><volume>35</volume>:<fpage>2535</fpage>-<lpage>2541</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28489510</pub-id></mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Teneriello</surname><given-names>M</given-names></name><name><surname>Powell</surname><given-names>MA</given-names></name><etal/></person-group>: <article-title>A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes</article-title>. <source>J Clin Oncol</source><volume>31</volume>, <year>2017</year> (<comment>supp; abstr 5520</comment>)</mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O‚ÄôMalley</surname><given-names>D</given-names></name><name><surname>Marabelle</surname><given-names>A</given-names></name><name><surname>De Jesus-Acosta</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study</article-title>. <source>Ann Oncol</source><volume>30</volume>:<fpage>v425</fpage>-<lpage>v426</lpage>, <year>2019</year> (<comment>supp; abstr 1044P</comment>)</mixed-citation>
              </ref>
              <ref id="b11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>de la Cruz-Merino</surname><given-names>L</given-names></name><name><surname>Petrella</surname><given-names>TM</given-names></name><etal/></person-group>: <article-title>Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination</article-title>. <source>J Clin Oncol</source><volume>41</volume>:<fpage>75</fpage>-<lpage>85</lpage>, <year>2023</year><pub-id pub-id-type="pmid">35867951</pub-id></mixed-citation>
              </ref>
              <ref id="b12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Glen</surname><given-names>H</given-names></name><etal/></person-group>: <article-title>Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial</article-title>. <source>Lancet Oncol</source><volume>16</volume>:<fpage>1473</fpage>-<lpage>1482</lpage>, <year>2015</year><pub-id pub-id-type="pmid">26482279</pub-id></mixed-citation>
              </ref>
              <ref id="b13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>R</given-names></name><name><surname>Alekseev</surname><given-names>B</given-names></name><name><surname>Rha</surname><given-names>SY</given-names></name><etal/></person-group>: <article-title>Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>1289</fpage>-<lpage>1300</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33616314</pub-id></mixed-citation>
              </ref>
              <ref id="b14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Schachter</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><etal/></person-group>: <article-title>Pembrolizumab versus ipilimumab in advanced melanoma</article-title>. <source>N Engl J Med</source><volume>372</volume>:<fpage>2521</fpage>-<lpage>2532</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25891173</pub-id></mixed-citation>
              </ref>
              <ref id="b15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlumberger</surname><given-names>M</given-names></name><name><surname>Tahara</surname><given-names>M</given-names></name><name><surname>Wirth</surname><given-names>LJ</given-names></name><etal/></person-group>: <article-title>Lenvatinib versus placebo in radioiodine-refractory thyroid cancer</article-title>. <source>N Engl J Med</source><volume>372</volume>:<fpage>621</fpage>-<lpage>630</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25671254</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
